Psyence Biomedical Ltd- 详细介绍、公司背景、业务范围、财务数据以及市场表现

关于 Psyence Biomedical Ltd 公司

Psyence Biomedical Ltd is a multi-asset, vertically integrated biopharmaceutical company specializing in psychedelic-based therapeutics. The Company is focused on developing nature-derived (non-synthetic) psilocybin-based psychedelic medicine. It is dedicated to addressing unmet mental health needs, particularly in palliative care. Its ongoing Phase IIb psilocybin clinical trial in Australia focuses on adjustment disorder in patients diagnosed with cancer.

Psyence Biomedical Ltd简介



公司代码PBM

公司名称Psyence Biomedical Ltd

上市日期Dec 10, 2021

CEOMaresky (Neil)

员工数量12

证券类型Ordinary Share

年结日Dec 10

公司地址121 Richmond Street West Penthouse

城市TORONTO

上市交易所NASDAQ OMX - NASDAQ BASIC

国家Canada

邮编M5H 2K1

电话17744604171

网址

公司代码PBM

上市日期Dec 10, 2021

CEOMaresky (Neil)

Psyence Biomedical Ltd公司高管



名称

名称/职务

职务

持股

持股变动

Mr. Marc Balkin

Independent Director

--

Dr. Jody Aufrichtig

Chairman of the Board, Strategic Business Development Officer

--

Dr. Neil Maresky

Chief Executive Officer, Director

--

Mr. Warwick Corden-Lloyd

Chief Financial Officer

--

Mr. Christopher (Chris) Bull

Independent Director

--

Dr. Seth Feuerstein

Independent Director

--

名称

名称/职务

职务

持股

持股变动

Mr. Marc Balkin

Independent Director

--

Dr. Jody Aufrichtig

Chairman of the Board, Strategic Business Development Officer

--

Dr. Neil Maresky

Chief Executive Officer, Director

--

Mr. Warwick Corden-Lloyd

Chief Financial Officer

--

Mr. Christopher (Chris) Bull

Independent Director

--

Dr. Seth Feuerstein

Independent Director

--

收入明细

由于公司未披露，未能获取相关数据

由于公司未披露，未能获取相关数据

业务

地区

由于公司未披露，未能获取相关数据

股东统计

更新时间: 1月2日周五

持股股东

股东类型

持股股东

占比

KAOS Capital Ltd

0.79%

Parallel Advisors, LLC

0.38%

White Lion Capital LLC

0.03%

Virtu Americas LLC

0.03%

AdvisorShares Investments, LLC

0.01%

其他

98.76%

持股股东

占比

KAOS Capital Ltd

0.79%

Parallel Advisors, LLC

0.38%

White Lion Capital LLC

0.03%

Virtu Americas LLC

0.03%

AdvisorShares Investments, LLC

0.01%

其他

98.76%

股东类型

持股股东

占比

Corporation

0.79%

Investment Advisor

0.41%

Research Firm

0.03%

Venture Capital

0.03%

其他

98.74%

机构持股



更新时间: 1月1日周四

报告期

机构数

持股数

持股占比

持股变动

2025Q4

32

189.44K

5.32%

-212.62K

2025Q3

38

319.64K

17.07%

+174.04K

2025Q2

45

357.80K

50.17%

+181.11K

2025Q1

45

167.96K

26.60%

+69.68K

2024Q4

82

948.20K

24.27%

+587.08K

2024Q3

88

169.92K

15.90%

-186.51K

2024Q2

92

159.62K

36.84%

-203.47K

2024Q1

96

157.41K

35.61%

-211.56K

2023Q4

88

18.95K

16.18%

-253.66K

2023Q3

87

16.58K

55.18%

-252.44K

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

KAOS Capital Ltd

313.88K

16.77%

+313.88K

--

Dec 08, 2025

Parallel Advisors, LLC

151.25K

8.08%

-123.75K

-45.00%

Sep 30, 2025

White Lion Capital LLC

12.55K

0.67%

+12.55K

--

Dec 04, 2024

Virtu Americas LLC

10.32K

0.55%

+10.32K

--

Sep 30, 2025

AdvisorShares Investments, LLC

5.38K

0.29%

+930.00

+20.91%

Sep 30, 2025

Osaic Holdings, Inc.

4.50K

0.24%

+4.50K

--

Sep 30, 2025

BofA Global Research (US)

3.34K

0.18%

--

Sep 30, 2025

Stonehage Fleming Financial Services Holdings, Ltd.

561.00

0.03%

--

Sep 30, 2025

持股ETF



更新时间: 12月6日周六

机构名称

占比

AdvisorShares Psychedelics ETF

0%

AdvisorShares Psychedelics ETF

占比0%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

除权除息日

类型

比率

Jan 14, 2026

Merger

6.25→1

May 01, 2025

Merger

7.97→1

Nov 12, 2024

Merger

75→1

Nov 12, 2024

Merger

75→1

Nov 12, 2024

Merger

75→1

Nov 12, 2024

Merger

75→1

公告日期

除权除息日

类型

比率

Jan 14, 2026

Merger

6.25→1

May 01, 2025

Merger

7.97→1

Nov 12, 2024

Merger

75→1

Nov 12, 2024

Merger

75→1

Nov 12, 2024

Merger

75→1

Nov 12, 2024

Merger

75→1